1 article found from author A. de Boer
By A. de Boer | G. Schenk
The delivery of hydrophilic drugs to the brain is limited by the various barriers in the brain. In this respect, the blood-brain barrier BBB is the most important barrier because it functions as a physical and metabolic barrier represented by the endothelial cells of brain capillaries. In order to treat brain diseases, drugs must pass the BBB by targeting them to internalizing transport systems at the BBB to overcome the BBB. In this paper, we summarize some approaches that may be successful for clinical application. The applicability of Cross Reacting Material CRM197 as a receptor-mediated targeting agent - particularly under disease induced circumstances - seems favorable and effective.